An India-wide proton therapy network backed by an investment of approximately ₹1,900 crore is being planned after Israeli medical technology company P-Cure Ltd signed an agreement with Indian healthcare company ARISTION Proton Center Private Limited. The first centre is planned at Sentient Health City in Bengaluru, followed by facilities in Kochi and a third major metropolitan city.
The agreement will bring P-Cure’s compact, synchrotron-based proton therapy systems to India for the first time, according to the report. ARISTION plans to deploy the systems through a dedicated network of centres rather than as standalone machine installations.
Proton therapy is a form of radiation treatment that uses high-energy protons instead of conventional X-rays to target and destroy cancer cells. The treatment is designed to deliver radiation with greater precision, according to the companies. The planned network will combine the therapy systems with an integrated artificial intelligence and augmented intelligence layer for patient care.
The first facility at Sentient Health City in Bengaluru is expected to serve as the starting point for the proposed network. ARISTION has also identified Kochi and another major metropolitan city for subsequent centres, although the supplied announcement does not specify the location of the third facility or provide an operational timeline.
The proposed investment is intended to fund a national network of proton therapy centres. ARISTION has positioned affordability and geographic access as central objectives of the model, indicating that the partnership is intended to expand access beyond isolated installations in a limited number of cities. Details of the planned treatment costs, financing structure, construction schedule and commissioning dates were not provided in the announcement.
Dr Lohith G Reddy, CMD and radiation oncologist at ARISTION Proton Center, said India already delivered world-class medical care but lacked proton and ion precision treatment at the scale required by a country of 1.4 billion people. He said P-Cure’s compact system provided the economics to build a national network and make advanced radiation therapy more accessible.
The partnership places specialised cancer-treatment infrastructure within a wider question of geographic access. The first three proposed locations span Bengaluru, Kochi and another metropolitan city, but the companies have not yet disclosed the eventual number of centres, the states to be covered or the mechanism through which patients from outside the host cities would access treatment.
The announcement marks the first planned deployment of P-Cure’s ultracompact proton therapy system in India. The next publicly stated steps are the establishment of the Bengaluru centre at Sentient Health City and the planned expansion to Kochi and a third major metropolitan location.
